Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The ups and downs of M&A

This article was originally published in Scrip

Executive Summary

The total value of global M&A activity in the life sciences and healthcare sector in the first quarter of 2009 exceeded that for the whole of 2008, according to a new report by the mergers and acquisitions intelligence service, mergermarket. The value of deals announced in the first three months of this year was $166 billion, in stark contrast to the $14.7 billion recorded for Q1 2008 and $114 billion recorded for the whole of 2008.

You may also be interested in...



Thirty-five Years Covering Health Care: The More Things Change…

The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.

Transcatheter Systems Set To Dominate Heart Valve Market

Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.

Bariatric Devices: Intragastric Balloons To Eclipse Gastric Banding

The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC001679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel